European Archives - Page 956 of 1157 - European Medical Journal

What is the Role of Ursodeoxycholic Acid for the Future Management of Patients with Primary Sclerosing Cholangitis in the Clinic and in Trials?

Primary sclerosing cholangitis (PSC) is a rare, progressive, cholestatic, immune-mediated hepatobiliary disease. It is characterised by inflammation…

Hepatitis E Virus Infection and Acute Non-Traumatic Neurological Injury

Hepatitis E virus (HEV) is endemic in many developed countries, with seroprevalence rates ranging from 4.7% in Scotland to 31.1% in France. Cases are…

Clinical Hepatocyte Cell Therapy: Challenges and Opportunities

The clinical application of hepatocyte transplants to treat patients with liver disease extends back to the early 1990s. Hepatocyte transplants are…

Specialist Nurses in Europe: Where Do We Stand?

Nurses and specialist nurses are playing a growing role in the healthcare system. Alongside the specialities already existing, such as…

Supporting Lifestyle Change Through Nurse-Led Motivation

The main focus of training hepatology care is to gain skills and enable nurses to specialise in hepatology. Skills and specialisation are gained through…

Diagnosis and Stage-Dependent Treatment of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is currently the second most common cause of cancer-related death worldwide, with the majority of all cases of HCC…

A Cardiologist’s Perspective on Social Media

Like it or hate it, social media, such as Twitter, Facebook, and Instagram, is having an impact on medicine. It is changing the way healthcare providers…

Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting

Oxford, UK and Conshohocken, US, 5 June, 2017 – Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer…

F-Star Expands Its Relationship with Merck Through a New Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology

Cambridge, UK, June 04, 2017 – F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck…

Darzalex®▼ (daratumumab) Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma

Beerse, Belgium, June 4, 2017 – Janssen-Cilag International NV (“Janssen”) today announced new data from updated analyses of the pivotal Phase 3 CASTOR…